NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2024 | $26.00 | Buy | Craig Hallum |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
| 8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens |
| 5/16/2023 | Outperform → Mkt Perform | Raymond James | |
| 5/9/2023 | $25.00 | Neutral → Buy | BTIG Research |
| 2/24/2023 | $20.00 | Hold → Buy | The Benchmark Company |
| 2/1/2023 | $15.00 | Hold → Buy | Needham |
| 8/26/2022 | Buy → Hold | The Benchmark Company |
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients. "Our presence at AMP 2024 underscores NeoGenomics' dedication to advancing cancer care through ongoing research in precision medicine," said Warren Stone, CCO of NeoGenomics. "By continuing to improve our methods and technologies, we aim to enhance outcomes and set new standards for oncology testing." NeoGeno
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City. The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer
Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00
BTIG Research reiterated coverage of NeoGenomics with a rating of Buy and set a new price target of $21.00 from $25.00 previously
Stephens upgraded NeoGenomics from Equal-Weight to Overweight and set a new price target of $18.00
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
3 - NEOGENOMICS INC (0001077183) (Issuer)
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM. Here's what investors need to know about the latest announcement. Earnings NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05. Revenue was up $19.02 million from the same period last year. Analysis of Past Earnings Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day. Here's a look at NeoGenomics's past performance: Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 EPS Estimate -0.05 -0.02 -0.08 -0.11 -0.15 EPS Actual -0.02 0.03 0 -0.05 -0.09 Revenue Estimate 149.89M
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $23 to $21.
Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. Third Quarter 2024 Highlights As Compared To Third Quarter 2023 Consolidated revenue increased 10% to $168 million Clinical Services revenue increased 14% to $146 million Advanced Diagnostics revenue decreased 10% to $22 million Net loss decreased 4% to $18 million Adjusted EBITDA increased 305% to positive $13 million "We delivered a strong third quarter, again gro
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time. The accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material t